 MONTREAL, March 24, 2021 GLOBE NEWSWIRE -- Theratechnologies Inc. Theratechnologies TSX: TH NASDAQ: THTX, a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the first patient received a dose of TH1902, its lead peptide-drug conjugate PDC for the treatment of sortilin positive SORT1 solid tumors. 